Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis (KPro-HP-Endo) (KPro-HP-Endo)
Primary Purpose
Corneal Transplantation, Glaucoma and Ocular Hypertension, Postoperative Complications
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy
Sponsored by
About this trial
This is an interventional prevention trial for Corneal Transplantation focused on measuring Boston keratoprosthesis type 1, Pars plana vitrectomy, Endoscopy
Eligibility Criteria
Inclusion Criteria:
- Aged from 18 to 80 years old
- Informed consent
- Boston keratoprosthesis candidate
- Pars plana vitrectomy candidate
- Ability to be followed for the duration of the study
Exclusion Criteria:
- Aged less than 18 or more than 80 years old
- Inability to give informed consent
- Repeat Boston keratoprosthesis
- Repeat pars plana vitrectomy
Sites / Locations
- Centre Hospitalier de l'Université de Montréal (CHUM)Recruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patients with KPro, PPV, and endoscopy
Arm Description
Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
Outcomes
Primary Outcome Measures
Rate of retroprosthetic membrane formation
Rate of postoperative retroprosthetic membrane formation behind the backplate of the Boston keratoprosthesis. Retroprosthetic membrane formation is diagnosed by the investigator using an examination of the anterior chamber performed at the slit-lamp.
Rate of retinal detachment
Rate of postoperative retinal detachment. Retinal detachment is diagnosed by the investigator using a dilated fundus (retinal) examination performed at the slit-lamp.
Rate of glaucoma development
Rate of development or progression of glaucoma, determined based on intraocular pressure increase of > 21 mmHg, increase of glaucoma medications, optic nerve excavation progression, or need to undergo glaucoma filtration surgery.
Secondary Outcome Measures
Proportion of patients with visual acuity better than 20/200
Proportion of patients with visual acuity better than 20/200 after surgery. The visual acuity is measured using the Snellen chart.
Change of visual acuity
Change of visual acuity compared between before and after surgery. The visual acuity is measured using the Snellen chart.
Time to retroprosthetic membrane formation after surgery
Time to retroprosthetic membrane formation, calculated in months from the time of the surgery. Retroprosthetic membrane formation behind the backplate of the Boston keratoprosthesis is diagnosed by the investigator using an examination of the anterior chamber performed at the slit-lamp.
Time to retinal detachment after surgery
Time to retinal detachment, calculated in months from the time of the surgery. Retinal detachment is diagnosed by the investigator using a dilated fundus (retinal) examination performed at the slit-lamp.
Proportion of participants requiring glaucoma surgery
Proportion of participants requiring glaucoma surgery (including glaucoma drainage device, trabeculectomy or cyclophotocoagulation) after the Boston keratoprothesis surgery.
Proportion of patients with visual field loss of 30% or more
Proportion of patients with visual field loss of 30% or more, measured using the automated Humphrey 24-2 visual field. The loss of 30% or more of visual field is calculated using the first two postoperative tests as a reference.
Proportion of patients with thinning of the nerve fiber layer
Proportion of patients with thinning of the nerve fiber layer, determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in average and for each of the four quadrants.
Rate of Boston keratoprosthesis complications
Rate of Boston keratoprosthesis complications. Complications from the Boston keratoprosthesis include: corneal melt, retroprosthetic membrane formation, retinal detachment, cystic macular edema, extrusion, hypotony, choroidal hemorrhage.
Full Information
NCT ID
NCT04337944
First Posted
April 3, 2020
Last Updated
July 24, 2023
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
1. Study Identification
Unique Protocol Identification Number
NCT04337944
Brief Title
Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis (KPro-HP-Endo)
Acronym
KPro-HP-Endo
Official Title
Impact of Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis in Reducing Postoperative Complications
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 8, 2020 (Actual)
Primary Completion Date
October 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Common complications of the Boston keratoprosthesis type 1 (KPro) surgery include retroprosthetic membrane formation, glaucoma, and retinal detachment. Often pars plana vitrectomy (PPV) is performed at the same time as KPro surgery for different indications. It has been shown to reduce postoperative complications in comparison to when it is performed after the KPro surgery. Patients who receive a complete PPV with peeling of the anterior hyaloid membrane have a lower incidence of retroprosthetic membrane formation and less vision loss due to glaucoma when compared to patients with partial PPV or anterior vitrectomy. During a complete PPV, peeling of the anterior hyaloid membrane is a difficult step because visualisation is poor, but it can be improved using endoscopy. The investigators suggest that peeling of the anterior hyaloid membrane assisted by endoscopy during KPro surgery would decrease postoperative complications in comparison to a PPV done after KPro surgery and without endoscopy.
Detailed Description
Boston keratoprosthesis type 1 (KPro) surgery is the most common corneal graft and is used to restore vision in patients with high risk of failure with traditional penetrating keratoplasty. Common complications of KPro surgery include retroprosthetic membrane formation behind the backplate of the KPro. Glaucoma is the most common threat to vision rehabilitation in patients with KPro. Glaucoma is often present before surgery and progresses after KPro, seven times faster than in patients with only glaucoma. Retinal detachment is a common posterior segment complication that arises post-KPro and can lead to a serious loss of vision. Pars plana vitrectomy (PPV) is the standard treatment for patients with vitreoretinal diseases and opacities. PPV can include peeling of the anterior hyaloid membrane to ensure total resection of the vitreous body. PPV allows for example for retroprosthetic membrane excision, installation or revision of a glaucoma drainage device, or repair of retinal detachment. Often PPV is performed at the same time as KPro surgery for different indications. It has been shown to reduce postoperative complications in comparison to when it is performed after the KPro surgery. Patients who receive a complete PPV with peeling of the anterior hyaloid membrane have a lower incidence of retroprosthetic membrane formation and less vision loss due to glaucoma when compared to patients with partial PPV or anterior vitrectomy. Combined surgeries of KPro and PPV offer a complete evaluation of the optic nerve and of the retina, which would not be possible otherwise. During a complete PPV, peeling of the anterior hyaloid membrane is a difficult step because visualisation is poor, especially with a KPro in place. Visualisation can be improved using endoscopy to visualize the inside of the eye over 360 degrees. The investigators suggest that peeling of the anterior hyaloid membrane assisted by endoscopy during KPro surgery would decrease postoperative complications in comparison to a PPV done after KPro surgery and without endoscopy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Corneal Transplantation, Glaucoma and Ocular Hypertension, Postoperative Complications, Vitrectomy, Endoscopy
Keywords
Boston keratoprosthesis type 1, Pars plana vitrectomy, Endoscopy
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Interventional prospective study on patients receiving a Boston keratoprosthesis type 1, using a retrospective group as the control group.
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients with KPro, PPV, and endoscopy
Arm Type
Experimental
Arm Description
Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
Intervention Type
Procedure
Intervention Name(s)
Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy
Intervention Description
Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
Primary Outcome Measure Information:
Title
Rate of retroprosthetic membrane formation
Description
Rate of postoperative retroprosthetic membrane formation behind the backplate of the Boston keratoprosthesis. Retroprosthetic membrane formation is diagnosed by the investigator using an examination of the anterior chamber performed at the slit-lamp.
Time Frame
12 months
Title
Rate of retinal detachment
Description
Rate of postoperative retinal detachment. Retinal detachment is diagnosed by the investigator using a dilated fundus (retinal) examination performed at the slit-lamp.
Time Frame
12 months
Title
Rate of glaucoma development
Description
Rate of development or progression of glaucoma, determined based on intraocular pressure increase of > 21 mmHg, increase of glaucoma medications, optic nerve excavation progression, or need to undergo glaucoma filtration surgery.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Proportion of patients with visual acuity better than 20/200
Description
Proportion of patients with visual acuity better than 20/200 after surgery. The visual acuity is measured using the Snellen chart.
Time Frame
12 months
Title
Change of visual acuity
Description
Change of visual acuity compared between before and after surgery. The visual acuity is measured using the Snellen chart.
Time Frame
12 months
Title
Time to retroprosthetic membrane formation after surgery
Description
Time to retroprosthetic membrane formation, calculated in months from the time of the surgery. Retroprosthetic membrane formation behind the backplate of the Boston keratoprosthesis is diagnosed by the investigator using an examination of the anterior chamber performed at the slit-lamp.
Time Frame
12 months
Title
Time to retinal detachment after surgery
Description
Time to retinal detachment, calculated in months from the time of the surgery. Retinal detachment is diagnosed by the investigator using a dilated fundus (retinal) examination performed at the slit-lamp.
Time Frame
12 months
Title
Proportion of participants requiring glaucoma surgery
Description
Proportion of participants requiring glaucoma surgery (including glaucoma drainage device, trabeculectomy or cyclophotocoagulation) after the Boston keratoprothesis surgery.
Time Frame
12 months
Title
Proportion of patients with visual field loss of 30% or more
Description
Proportion of patients with visual field loss of 30% or more, measured using the automated Humphrey 24-2 visual field. The loss of 30% or more of visual field is calculated using the first two postoperative tests as a reference.
Time Frame
12 months
Title
Proportion of patients with thinning of the nerve fiber layer
Description
Proportion of patients with thinning of the nerve fiber layer, determined by Spectral Domain Optical Coherence Tomography (SD-OCT) in average and for each of the four quadrants.
Time Frame
12 months
Title
Rate of Boston keratoprosthesis complications
Description
Rate of Boston keratoprosthesis complications. Complications from the Boston keratoprosthesis include: corneal melt, retroprosthetic membrane formation, retinal detachment, cystic macular edema, extrusion, hypotony, choroidal hemorrhage.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Aged from 18 to 80 years old
Informed consent
Boston keratoprosthesis candidate
Pars plana vitrectomy candidate
Ability to be followed for the duration of the study
Exclusion Criteria:
Aged less than 18 or more than 80 years old
Inability to give informed consent
Repeat Boston keratoprosthesis
Repeat pars plana vitrectomy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie-Catherine Tessier, M.Sc.
Phone
1-514-890-8000
Ext
11550
Email
marie-catherine.tessier.chum@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Dominique Geoffrion, B.Sc.
Phone
1-514-890-8000
Ext
11550
Email
dominique.geoffrion@mail.mcgill.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mona Harissi-Dagher, MD
Organizational Affiliation
Centre hospitalier de l'Université de Montréal (CHUM)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Hospitalier de l'Université de Montréal (CHUM)
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 3E4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Catherine Tessier, M.Sc.
Phone
1-514-890-8000
Ext
11550
Email
marie-catherine.tessier.chum@ssss.gouv.qc.ca
First Name & Middle Initial & Last Name & Degree
Mona Harissi-Dagher, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32066560
Citation
Szigiato AA, Bostan C, Nayman T, Harissi-Dagher M. Long-term visual outcomes of the Boston type I keratoprosthesis in Canada. Br J Ophthalmol. 2020 Nov;104(11):1601-1607. doi: 10.1136/bjophthalmol-2019-315345. Epub 2020 Feb 17.
Results Reference
background
PubMed Identifier
25174898
Citation
Wang Q, Harissi-Dagher M. Characteristics and management of patients with Boston type 1 keratoprosthesis explantation--the University of Montreal Hospital Center experience. Am J Ophthalmol. 2014 Dec;158(6):1297-1304.e1. doi: 10.1016/j.ajo.2014.08.037. Epub 2014 Aug 28.
Results Reference
background
PubMed Identifier
23579405
Citation
Harissi-Dagher M, Durr GM, Biernacki K, Sebag M, Rheaume MA. Pars plana vitrectomy through the Boston Keratoprosthesis type 1. Eye (Lond). 2013 Jun;27(6):767-9. doi: 10.1038/eye.2013.58. Epub 2013 Apr 12.
Results Reference
background
PubMed Identifier
23435225
Citation
Robert MC, Pomerleau V, Harissi-Dagher M. Complications associated with Boston keratoprosthesis type 1 and glaucoma drainage devices. Br J Ophthalmol. 2013 May;97(5):573-7. doi: 10.1136/bjophthalmol-2012-302770. Epub 2013 Feb 23.
Results Reference
background
PubMed Identifier
22017851
Citation
Moussally K, Harissi-Dagher M. Long-term complications associated with glaucoma drainage devices and Boston keratoprosthesis. Am J Ophthalmol. 2011 Nov;152(5):883-4; author reply 884-5. doi: 10.1016/j.ajo.2011.07.014. No abstract available.
Results Reference
background
PubMed Identifier
21982110
Citation
Talajic JC, Agoumi Y, Gagne S, Moussally K, Harissi-Dagher M. Prevalence, progression, and impact of glaucoma on vision after Boston type 1 keratoprosthesis surgery. Am J Ophthalmol. 2012 Feb;153(2):267-274.e1. doi: 10.1016/j.ajo.2011.07.022. Epub 2011 Oct 7.
Results Reference
background
PubMed Identifier
31453878
Citation
Dohlman CH, Zhou C, Lei F, Cade F, Regatieri CV, Crnej A, Dohlman JG, Shen LQ, Paschalis EI. Glaucoma After Corneal Trauma or Surgery-A Rapid, Inflammatory, IOP-Independent Pathway. Cornea. 2019 Dec;38(12):1589-1594. doi: 10.1097/ICO.0000000000002106.
Results Reference
background
PubMed Identifier
24531120
Citation
Crnej A, Paschalis EI, Salvador-Culla B, Tauber A, Drnovsek-Olup B, Shen LQ, Dohlman CH. Glaucoma progression and role of glaucoma surgery in patients with Boston keratoprosthesis. Cornea. 2014 Apr;33(4):349-54. doi: 10.1097/ICO.0000000000000067.
Results Reference
background
PubMed Identifier
17450007
Citation
Khan BF, Harissi-Dagher M, Khan DM, Dohlman CH. Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation. Int Ophthalmol Clin. 2007 Spring;47(2):61-71. doi: 10.1097/IIO.0b013e318036bd8b. No abstract available.
Results Reference
background
PubMed Identifier
25633467
Citation
Boscher C, Kuhn F. Endoscopic evaluation and dissection of the anterior vitreous base. Ophthalmic Res. 2015;53(2):90-9. doi: 10.1159/000370032. Epub 2015 Jan 27.
Results Reference
background
PubMed Identifier
25325859
Citation
Modjtahedi BS, Eliott D. Vitreoretinal complications of the Boston Keratoprosthesis. Semin Ophthalmol. 2014 Sep-Nov;29(5-6):338-48. doi: 10.3109/08820538.2014.959204.
Results Reference
background
PubMed Identifier
29600187
Citation
Yu YZ, Zou YP, Zou XL. Endoscopy-assisted vitrectomy in the anterior vitreous. Int J Ophthalmol. 2018 Mar 18;11(3):506-511. doi: 10.18240/ijo.2018.03.23. eCollection 2018.
Results Reference
background
Learn more about this trial
Endoscopic Assisted Anterior Hyaloid Peeling in Boston Type 1 Keratoprosthesis (KPro-HP-Endo)
We'll reach out to this number within 24 hrs